CN101939014B - 亚硝酸盐在慢性缺血中的应用 - Google Patents

亚硝酸盐在慢性缺血中的应用 Download PDF

Info

Publication number
CN101939014B
CN101939014B CN200880116483.4A CN200880116483A CN101939014B CN 101939014 B CN101939014 B CN 101939014B CN 200880116483 A CN200880116483 A CN 200880116483A CN 101939014 B CN101939014 B CN 101939014B
Authority
CN
China
Prior art keywords
nitrite
tissue
ischemic
chronic
sodium nitrite
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200880116483.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN101939014A (zh
Inventor
克里斯托弗·凯维尔
大卫·勒费
拉凯什·帕特尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UAB Research Foundation
Louisiana State University
Original Assignee
UAB Research Foundation
Louisiana State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UAB Research Foundation, Louisiana State University filed Critical UAB Research Foundation
Publication of CN101939014A publication Critical patent/CN101939014A/zh
Application granted granted Critical
Publication of CN101939014B publication Critical patent/CN101939014B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN200880116483.4A 2007-11-15 2008-11-17 亚硝酸盐在慢性缺血中的应用 Expired - Fee Related CN101939014B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US315007P 2007-11-15 2007-11-15
US61/003,150 2007-11-15
PCT/US2008/083830 WO2009065142A2 (en) 2007-11-15 2008-11-17 Use of nitrite salts in chronic ischemia

Publications (2)

Publication Number Publication Date
CN101939014A CN101939014A (zh) 2011-01-05
CN101939014B true CN101939014B (zh) 2016-04-27

Family

ID=40639493

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880116483.4A Expired - Fee Related CN101939014B (zh) 2007-11-15 2008-11-17 亚硝酸盐在慢性缺血中的应用

Country Status (7)

Country Link
US (2) US9649334B2 (https=)
EP (1) EP2219657A4 (https=)
JP (2) JP5795165B2 (https=)
CN (1) CN101939014B (https=)
AU (1) AU2008322437B2 (https=)
IL (1) IL205720A (https=)
WO (1) WO2009065142A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2219657A4 (en) 2007-11-15 2020-01-08 Louisiana State University USE OF NITRITE SALTS IN CHRONIC ISCHEMIA
US8568793B2 (en) * 2009-02-11 2013-10-29 Hope Medical Enterprises, Inc. Sodium nitrite-containing pharmaceutical compositions
US20120237617A1 (en) * 2009-06-18 2012-09-20 Theravasc Inc. Use of nitrite salts in treating tissue damage
CA2777066C (en) 2009-10-14 2020-02-18 TheraVasc, LLC Pharmaceutical formulations of nitrite and uses thereof
US20130209584A1 (en) * 2009-10-14 2013-08-15 Theravasc Inc. Pharmaceutical formulations of nitrite and uses thereof
CA2899602C (en) 2013-02-20 2024-01-30 Theravasc Inc. Pharmaceutical uses of inorganic nitrites
US10517817B2 (en) 2013-05-09 2019-12-31 Syk Technologies, Llc Deep topical systemic nitric oxide therapy apparatus and method
WO2017132275A1 (en) 2016-01-27 2017-08-03 Syk Technologies, Llc Nitric oxide topical application apparatus and methods
TWI698241B (zh) 2017-09-05 2020-07-11 國立成功大學 用於治療缺血的肝素組合物
WO2020141546A1 (en) 2019-01-02 2020-07-09 Celagenex Research (India) Pvt. Ltd. Synergistic nutritional compositions for pain management
US12459820B2 (en) 2020-06-11 2025-11-04 J. W. Randolph Miller Stabilized and NO2-inhibited nitric oxide generating gels for inhaled nitric oxide therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060182815A1 (en) * 2004-07-09 2006-08-17 Use of nitrite salts for the treatment of cardiovascular conditions

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2914446A (en) 1958-06-26 1959-11-24 Upjohn Co Nitrite stabilized ascorbic acid-cyanocobalamin compositions
US4650484A (en) 1983-02-03 1987-03-17 Alza Corporation Method for treating ischemic conditions
IE64726B1 (en) 1987-11-20 1995-08-23 Elan Corp Plc Pharmaceutical formulations for preventing drug tolerance
US5122384A (en) 1989-05-05 1992-06-16 Kv Pharmaceutical Company Oral once-per-day organic nitrate formulation which does not induce tolerance
US5278192A (en) 1992-07-02 1994-01-11 The Research Foundation Of State University Of New York Method of vasodilator therapy for treating a patient with a condition
US6709681B2 (en) 1995-02-17 2004-03-23 Aberdeen University Acidified nitrite as an antimicrobial agent
US20110196039A9 (en) 1994-10-05 2011-08-11 Kaesemeyer Wayne H Controlled release arginine formulations
US5648101A (en) * 1994-11-14 1997-07-15 Tawashi; Rashad Drug delivery of nitric oxide
US5770645A (en) 1996-08-02 1998-06-23 Duke University Medical Center Polymers for delivering nitric oxide in vivo
US5994444A (en) 1997-10-16 1999-11-30 Medtronic, Inc. Polymeric material that releases nitric oxide
US7371415B1 (en) 1998-04-03 2008-05-13 The Daily Wellness Company Method and composition for improving sexual fitness
US7015876B1 (en) 1998-06-03 2006-03-21 Lear Corporation Heads-up display with improved contrast
US6103275A (en) * 1998-06-10 2000-08-15 Nitric Oxide Solutions Systems and methods for topical treatment with nitric oxide
WO2000003725A1 (en) 1998-07-14 2000-01-27 Paracelsian, Inc. Method for identifying and confirming consistent bio-functionality of natural compositions
US6962717B1 (en) 1999-01-29 2005-11-08 Disphar International B.V. Pharmaceutical compositions
GB9905425D0 (en) 1999-03-09 1999-05-05 Queen Mary & Westfield College Pharmaceutical composition
US6314956B1 (en) 1999-09-08 2001-11-13 Duke University Pulmonary delivery of NO group-containing compound in gas form to treat respiratory, cardiac and blood disorders
CN1299690C (zh) * 2000-07-28 2007-02-14 生物能量公司 用于提高心血管功能的组合物
GB0119011D0 (en) 2001-08-03 2001-09-26 Univ Aberdeen Treatment of nail infections
EP1492509A1 (en) 2001-12-18 2005-01-05 ALZA Corporation Dosage form providing time-varying patterns of drug delivery
EP1336602A1 (en) 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
CA2379211A1 (fr) 2002-03-28 2003-09-28 Institut De Cardiologie De Montreal Utilisation du bleu de methylene pour renverser la reaction hemodynamique exageree induite par la combinaison d'un derive nitre et du sildenafil ou d'une molecule de meme classe (inhibiteur de la phosphodiesterase)
ES2294543T3 (es) 2003-07-09 2008-04-01 The Government Of The United States Of America, As Represented By The Secretary, Department Of Heal Uso de sales de nitrilo para el tratamiento de afecciones cardiovasculares.
JP2007502831A (ja) 2003-08-20 2007-02-15 ニトロメッド インコーポレーティッド ニトロソ化およびニトロシル化心血管化合物、組成物、ならびに使用方法
WO2005023189A2 (en) * 2003-09-03 2005-03-17 Pharmacia Corporation Method of cox-2 selective inhibitor and nitric oxide-donating agent
US20060083824A1 (en) 2004-10-20 2006-04-20 Pbm Products Llc Nutritional supplements for glucose intolerant individuals
AU2006249771A1 (en) 2005-05-24 2006-11-30 Wellgen, Inc. Compositions and methods for the prevention and treatment of conditions associated with inflammation
WO2007094827A2 (en) 2006-02-10 2007-08-23 Mannatech, Inc. All natural multivitamin and multimineral dietary supplement formulations for enhanced absorption and biological utilization
GB0607402D0 (en) * 2006-04-12 2006-05-24 Barts & London Nhs Trust Therapeutic composition and use
US8333997B2 (en) * 2006-06-21 2012-12-18 Albert Einstein College Of Medicine Of Yeshiva University Compositions for sustained release of nitric oxide, methods of preparing same and uses thereof
DK2124638T3 (en) 2007-02-26 2017-03-20 Heartbeet Ltd COMPOSITION INCREASING PERFORMANCE AND USING IT
CA2678097C (en) * 2007-02-26 2023-03-14 Jon Lundberg New use of nitrites and nitrates and compositions containing these
WO2008153762A2 (en) 2007-05-25 2008-12-18 N30 Pharmaceuticals, Llc S-nitrosothiol formulations and storage systems
EP2219657A4 (en) 2007-11-15 2020-01-08 Louisiana State University USE OF NITRITE SALTS IN CHRONIC ISCHEMIA
WO2009086470A2 (en) 2007-12-27 2009-07-09 Aires Pharmaceuticals, Inc. Aerosolized nitrite and nitric oxide - donating compounds and uses thereof
WO2010036236A1 (en) 2008-09-23 2010-04-01 Baker Hughes Incorporated Anchor assembly
US8568793B2 (en) 2009-02-11 2013-10-29 Hope Medical Enterprises, Inc. Sodium nitrite-containing pharmaceutical compositions
US20120237617A1 (en) 2009-06-18 2012-09-20 Theravasc Inc. Use of nitrite salts in treating tissue damage
CA2777066C (en) 2009-10-14 2020-02-18 TheraVasc, LLC Pharmaceutical formulations of nitrite and uses thereof
US20130209584A1 (en) 2009-10-14 2013-08-15 Theravasc Inc. Pharmaceutical formulations of nitrite and uses thereof
WO2012135623A1 (en) 2011-03-31 2012-10-04 Theravasc Inc. Use of nitrites for the treatment of cerebral amyloid angiopathy, age associated dementia, and cognitive decline
US20140112983A1 (en) 2011-04-14 2014-04-24 Theravasc Inc. Nitrite compositions and uses thereof
US9294956B2 (en) 2011-12-29 2016-03-22 Qualcomm Incorporated Application-server-assisted preemptive multicast bearer establishment for real-time low-latency applications
CA2899602C (en) * 2013-02-20 2024-01-30 Theravasc Inc. Pharmaceutical uses of inorganic nitrites

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060182815A1 (en) * 2004-07-09 2006-08-17 Use of nitrite salts for the treatment of cardiovascular conditions

Also Published As

Publication number Publication date
IL205720A0 (en) 2010-11-30
US9649334B2 (en) 2017-05-16
US10864229B2 (en) 2020-12-15
JP5795165B2 (ja) 2015-10-14
JP5908527B2 (ja) 2016-04-26
CN101939014A (zh) 2011-01-05
WO2009065142A2 (en) 2009-05-22
EP2219657A2 (en) 2010-08-25
IL205720A (en) 2015-08-31
AU2008322437B2 (en) 2013-11-07
EP2219657A4 (en) 2020-01-08
US20110311653A1 (en) 2011-12-22
JP2011503212A (ja) 2011-01-27
JP2014139255A (ja) 2014-07-31
US20170312310A1 (en) 2017-11-02
AU2008322437A1 (en) 2009-05-22

Similar Documents

Publication Publication Date Title
CN101939014B (zh) 亚硝酸盐在慢性缺血中的应用
Koneru et al. Sildenafil‐mediated neovascularization and protection against myocardial ischaemia reperfusion injury in rats: role of VEGF/angiopoietin‐1
JP2000510460A (ja) スクアラミンを他の抗癌剤と併用する上皮性悪性腫瘍の治療
KR20170137919A (ko) 조직 복구 및 재생 방법
Penumathsa et al. Secoisolariciresinol diglucoside induces neovascularization-mediated cardioprotection against ischemia–reperfusion injury in hypercholesterolemic myocardium
CN104602699B (zh) 含c‑肽的用于预防或治疗糖尿病性血管生成损伤的组合物
US10596188B2 (en) Use of nitrite salts in treating tissue damage
EP3154551B1 (en) The use of dextran sulfate having an average molecular weight below 10000 da for inducing angiogenisis in a subject
AU2017365926B2 (en) Treatments for heart failure and cardiac ischaemic reperfusion injury
Recchia et al. Cytokines are not a Requisite Part of the Pathophysiology Leading to Cardiac Decompensation (44461)
Cohen et al. Longitudinal changes in myocardial basic fibroblast growth factor (FGF-2) activity following coronary artery ligation in the dog
WO2015190989A1 (en) The use of dextran sulfate having an average molecular weight below 10000 da for inducing angiogenisis in a subject
BLACKFORD et al. Captopril provides sustained hemodynamic benefits in dogs with experimentally induced mitral regurgitation
KR20210013543A (ko) 내피 세포 기능장애를 조절하기 위한 rps2 펩타이드의 용도
HK1152657A (en) Use of nitrite salts in chronic ischemia
HK1152657B (en) Use of nitrite salts in chronic ischemia
TWI774059B (zh) Ｃｘｃｌ５中和抗體用於製備預防或治療周邊動脈阻塞疾病的藥物的用途
US20250152613A1 (en) Compositions and methods for covid-19 treatment
Karamanlidis et al. PO-05-128 TARGETED ANTIBODY-OLIGONUCLEOTIDE CONJUGATE THERAPY REDUCES PRKAG2 MRNA IN CARDIAC TISSUE OF NON-HUMAN PRIMATES: A PROMISING APPROACH FOR PRKAG2 SYNDROME
CN120459270A (zh) OpiCa1或其纳米脂质体在制备治疗和/或预防心肌纤维化相关疾病药物中的应用
Tetens et al. Alterations in systemic and local colonic hemodynamic variables associated with intravenous infusion of ATP-MgCl2 in healthy anesthetized horses
Belikoff et al. Hyperbaric Oxygen and Endothelial Responses in Wound Healing and Ischemia–Reperfusion Injury
US20170072012A1 (en) Use of gsmtx4 to reduce ischemia reperfusion injury
Niroomand Supernormal conduction mimicking a supraventricular capture beat during wide complex tachycardia

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1152657

Country of ref document: HK

C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: louisiana

Applicant after: BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL College THROUGH THE LSU AGCENTER

Applicant after: THE UAB RESEARCH FOUNDATION

Address before: louisiana

Applicant before: Louisiana State University

Applicant before: The UAB Research Foundation

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: LOUISIANA STATE UNIVERSITY TO: UNIV LOUISIANA STATE

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1152657

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160427